A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|19|3481-3490

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.19, 2015-10, pp. : 3481-3490

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTORC1 et sirolimus

By Tartarin Pauline   Froment Pascal  

Médecine/sciences, Vol. 29, Iss. 2, 2013-02 ,pp. : 200-205

Edp Sciences

Access to resources Recommend Favorite

A phase 2a randomized, double‐blind, placebo‐controlled, sequential dose‐escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate‐to‐severe psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 3, 2015-09 ,pp. : 767-776

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 2a randomized, double‐blind, placebo‐controlled, sequential dose‐escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate‐to‐severe psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 7-0963, Iss. 3, 2015-09 ,pp. : 767-776

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Dose-Escalation Study of Oxaliplatin and Vinorelbine in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 63, Iss. 3, 2002-10 ,pp. : 213-218

Karger

Access to resources Recommend Favorite

Phase 1, open‐label, dose escalation, safety, and pharmacokinetics study of ME‐344 as a single agent in patients with refractory solid tumors

By  

CANCER, Vol. 121, Iss. 7, 2015-04 ,pp. : 1056-1063

John Wiley & Sons Inc

Access to resources Recommend Favorite